Statins, the renin-angiotensin-aldosterone system and hypertension - A tale of another beneficial effect of statins

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 15, Issue 3, 2014, Pages 250-258

  Drapala, Adrian ^a   Sikora, Mariusz ^a   Ufnal, Marcin ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

aldosterone; angiotensin; cardiovascular disease; hypercholesterolaemia; hypertension; renin angiotensin aldosterone system; Statins

Indexed keywords

ANGIOTENSIN II; ATORVASTATIN; COMPACTIN; ENALAPRIL; FLUINDOSTATIN; FOSINOPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTERIOSCLEROSIS; ARTICLE; DRUG POTENTIATION; DYSLIPIDEMIA; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATION; INTRACELLULAR SIGNALING; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; BLOOD PRESSURE; DRUG EFFECTS; PATHOPHYSIOLOGY;

BLOOD PRESSURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 84909977812     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320314531058     Document Type: Article

References (146)

1. Tiegerstedt R, Bergman P. Niere und Kreislauf. Skand Arch Physiol. 1898 ; 8: 223-271
2. Atlas SA. The renin-angiotensin aldosterone system: Pathophysiological role and pharmacologic inhibition. J Manag Care Pharm. 2007 ; 13: 9-20
3. Crowley SD, Coffman TM. Recent advances involving the renin-angiotensin system. Experimental cell research. 2012 ; 318: 1049-1056
4. McKinley MJ, Albiston AL, Allen AM, et al. The brain renin-angiotensin system: Location and physiological roles. Int J Biochem Cell Biol. 2003 ; 35: 901-918
5. Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006 ; 86: 747-803
6. Phillips MI, Sumners C. Angiotensin II in central nervous system physiology. Regul Pept. 1998 ; 78: 1-11
7. Seva Pessoa B, van der Lubbe N, Verdonk K, et al. Key developments in renin-angiotensin-aldosterone system inhibition. Nat Rev Nephrol. 2013 ; 9: 26-36
8. Adams KF. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure. Am J Health Syst Pharm. 2004 ; 61: S4 - S13
9. Durante A, Peretto G, Laricchia A, et al. Role of the renin-angiotensin-aldosterone system in the pathogenesis of atherosclerosis. Curr Pharm Des. 2012 ; 18: 981-1004
10. Simoes ESAC, Flynn JT. The renin-angiotensin-aldosterone system in 2011: Role in hypertension and chronic kidney disease. Pediatr Nephrol. 2012 ; 27: 1835-1845
11. Biollaz J, Brunner HR, Gavras I, et al. Antihypertensive therapy with MK 421: Angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982 ; 4: 966-972
12. Mento PF, Wilkes BM. Plasma angiotensins and blood pressure during converting enzyme inhibition. Hypertension. 1987 ; 9: III42 - III48
13. Bader M, Santos RA, Unger T, et al. New therapeutic pathways in the RAS. J Renin Angiotensin Aldosterone Syst. 2012 ; 13: 505-508
14. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomised controlled trials. Brit Med J. 2009 ; 338: b2376
15. Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010 ; 376: 1670-1681
16. de Vries FM, Denig P, Pouwels KB, et al. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: A meta-analysis. Drugs. 2012 ; 72: 2365-2373
17. Preiss D, Sattar N. Lipids, lipid modifying agents and cardiovascular risk: A review of the evidence. Clin Endocrinol (Oxf). 2009 ; 70: 815-828
18. Rosenson RS. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs. 2001 ; 1: 411-420
19. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013 ; 1:
20. Collins R, Armitage J, Parish S, et al. and the Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004 ; 363: 757-767
21. Silva T, Teixeira J, Remiao F, et al. Alzheimer's disease, cholesterol, and statins: The junctions of important metabolic pathways. Angew Chem Int Ed Engl. 2013 ; 52: 1110-1121
22. Delahoy PJ, Magliano DJ, Webb K, et al. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clin Ther. 2009 ; 31: 236-244
23. Robinson JG, Smith B, Maheshwari N, et al. Pleiotropic effects of statins: Benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol. 2005 ; 46: 1855-1862
24. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)-can C-reactive protein be used to target statin therapy in primary prevention?. Am J Cardiol. 2006 ; 97: 33A - 41A
25. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2013 ;:
26. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 ;:
27. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J Antibiot (Tokyo). 1976 ; 29: 1346-1348
28. Brown AG, Smale TC, King TJ, et al. Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum. J Chem Soc Perkin. 1: 1976 1165-1170
29. Weng TC, Yang YH, Lin SJ, et al. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010 ; 35: 139-51
30. Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J. 2006 ; 151: 273-281
31. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999 ; 84: 413-428
32. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet. 2008 ; 47: 463-474
33. Reinoso RF, Sanchez Navarro A, Garcia MJ, et al. Preclinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol. 2002 ; 24: 593-613
34. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: An update. Fundam Clin Pharmacol. 2005 ; 19: 117-125
35. Koga T, Kikuchi T, Miyazaki A, et al. Tissue-selective inhibition of sterol synthesis in mice by pravastatin sodium after a single or repeated oral administrations. Lipids. 1995 ; 30: 775-779
36. Tsuji A, Saheki A, Tamai I, et al. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther. 1993 ; 267: 1085-1090
37. Grundy SM. Cholesterol metabolism in man. West J Med. 1978 ; 128: 13-25
38. Endo A, Tsujita Y, Kuroda M, et al. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur J Biochem. 1977 ; 77: 31-36
39. Forster LF, Stewart G, Bedford D, et al. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates. Atherosclerosis. 2002 ; 164: 129-145
40. Yamashita S, Tsubakio-Yamamoto K, Ohama T, et al. Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J Atheroscler Thromb. 2010 ; 17: 436-451
41. Shepherd J. Profiling risk and new therapeutic interventions: Looking ahead. Am J Med. 1998 ; 104: 19S - 22S
42. Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering-are they clinically relevant?. Eur Heart J. 2003 ; 24: 225-248
43. Jasinska M, Owczarek J, Orszulak-Michalak D. Statins: A new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol Rep. 2007 ; 59: 483-499
44. McGowan CL, Murai H, Millar PJ, et al. Simvastatin reduces sympathetic outflow and augments endothelium-independent dilation in non-hyperlipidaemic primary hypertension. Heart. 2013 ; 99: 240-246
45. Sarkar K, Sinha AK, Mehta JL. The role of statins in endothelial dysfunction in hypertension. Curr Opin Cardiol. 2006 ; 21: 316-321
46. Quist-Paulsen P. Statins and inflammation: An update. Curr Opin Cardiol. 2010 ; 25: 399-405
47. Wassmann S, Laufs U, Muller K, et al. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol. 2002 ; 22: 300-305
48. Aviram M, Dankner G, Cogan U, et al. Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies. Metabolism. 1992 ; 41: 229-235
49. de Sotomayor MA, Perez-Guerrero C, Herrrera MD, et al. Improvement of age-related endothelial dysfunction by simvastatin: Effect on NO and COX pathways. Br J Pharmacol. 2005 ; 146: 1130-1138
50. Kaesemeyer WH, Caldwell RB, Huang J, et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol. 1999 ; 33: 234-241
51. Lahera V, Goicoechea M, de Vinuesa SG, et al. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: Beneficial effects of statins. Curr Med Chem. 2007 ; 14: 243-248
52. Du B, Xu G, Cao H, et al. Effects of atorvastatin on expression of ICAM-1 in atherosclerotic rabbits. J Cardiovasc Med. 2013 ; 14: 120-126
53. Yang JC, Huang F, Wu CJ, et al. Simvastatin reduces VCAM-1 expression in human umbilical vein endothelial cells exposed to lipopolysaccharide. Inflamm Res. 2012 ; 61: 485-491
54. Pruefer D, Scalia R, Lefer AM. Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. Arterioscler Thromb Vasc Biol. 1999 ; 19: 2894-2900
55. Weber C, Erl W, Weber KS, et al. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997 ; 30: 1212-1217
56. Yoshida M, Sawada T, Ishii H, et al. Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: Involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol. 2001 ; 21: 1165-1171
57. Diomede L, Albani D, Sottocorno M, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol. 2001 ; 21: 1327-1332
58. Kothe H, Dalhoff K, Rupp J, et al. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation. 2000 ; 101: 1760-1763
59. Ando H, Takamura T, Ota T, Nagai Y, et al. Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis. J Pharmacol Exp Ther. 2000 ; 294: 1043-1046
60. Rosenson RS, Tangney CC, Casey LC. Inhibition of proinflammatory cytokine production by pravastatin. Lancet. 1999 ; 353: 983-984
61. Wang HR, Li JJ, Huang CX, Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein. Clin Chim Acta. 2005 ; 353: 53-60
62. Chan KY, Boucher ES, Gandhi PJ, et al. HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health Syst Pharm. 2004 ; 61: 1676-1681
63. Huang KC, Chen CW, Chen JC, et al. HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. J Biomed Sci. 2003 ; 10: 396-405
64. Dichtl W, Dulak J, Frick M, et al. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2003 ; 23: 58-63
65. Kleemann R, Verschuren L, de Rooij BJ, et al. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro. Blood. 2004 ; 103: 4188-4194
66. Alvarez E, Rodino-Janeiro BK, Ucieda-Somoza R, et al. Pravastatin counteracts angiotensin II-induced upregulation and activation of NADPH oxidase at plasma membrane of human endothelial cells. J Cardiovasc Pharmacol. 2010 ; 55: 203-212
67. Inami S, Okamatsu K, Takano M, et al. Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia. Jpn Heart J. 2004 ; 45: 969-975
68. Singh U, Jialal I. Oxidative stress and atherosclerosis. Pathophysiology. 2006 ; 13: 129-142
69. Kosmidou I, Moore JP, Weber M, et al. Statin treatment and 3' polyadenylation of eNOS mRNA. Arterioscler Thromb Vasc Biol. 2007 ; 27: 2642-2649
70. Laufs U, La Fata V, Plutzky J, et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998 ; 97: 1129-1135
71. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am J Physiol. 1986 ; 250: H822 - H827
72. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: Molecular mechanisms and clinical results. Trends Mol Med. 2008 ; 14: 37-44
73. Muhlhauser U, Zolk O, Rau T, et al. Atorvastatin desensitizes beta-adrenergic signaling in cardiac myocytes via reduced isoprenylation of G-protein gamma-subunits. FASEB J. 2006 ; 20: 785-787
74. Swedberg K, et al. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med. 1987 ; 316: 1429-1435
75. Ball SG, Cowan JC, Winter C, et al. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993 ; 342: 821-828
76. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet. 2000 ; 355: 1575-1581
77. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 ; 358: 1547-1559
78. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation. 2004 ; 110: 3687-3692
79. Sposito AC, Mansur AP, Coelho OR, et al. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril). Am J Cardiol. 1999 ; 83: 1497-1499
80. Libby P, Okamoto Y, Rocha VZ, et al. Inflammation in atherosclerosis: Transition from theory to practice. Circ J. 2010 ; 74: 213-220
81. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept. 2000 ; 93: 65-77
82. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 2001 ; 103: 276-283
83. Fukumoto Y, Libby P, Rabkin E, et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 2001 ; 103: 993-999
84. Libby P, Sasiela W. Plaque stabilization: Can we turn theory into evidence?. Am J Cardiol. 2006 ; 98: 26P - 33P
85. Mitani H, Egashira K, Kimura M. HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent "direct" effects on atherosclerotic vessels in high cholesterol diet-fed rabbits. Pharmacol Res. 2003 ; 48: 417-427
86. Dechend R, Fiebler A, Lindschau C, et al. Modulating angiotensin II-induced inflammation by HMG Co-A reductase inhibition. Am J Hypertens. 2001 ; 14: 55S - 61S
87. Chen J, Mehta JL. Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: Blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol. 2006 ; 291: H1738 - H1745
88. Xu Z, Okamoto H, Akino M, et al. Pravastatin attenuates left ventricular remodeling and diastolic dysfunction in angiotensin II-induced hypertensive mice. J Cardiovasc Pharmacol. 2008 ; 51: 62-70
89. Dampney RA. Brain angiotensin and heart failure: Further evidence for a critical role of mitogen-activated protein kinases. Hypertension. 2008 ; 52: 621-622
90. Francis J, Wei SG, Weiss RM, et al. Brain angiotensin-converting enzyme activity and autonomic regulation in heart failure. Am J Physiol Heart Circ Physiol. 2004 ; 287: H2138 - H2146
91. Cleland JG, McMurray JJ, Kjekshus J, et al. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: Prediction of cardiovascular events and interaction with the effects of rosuvastatin: A report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol. 2009 ; 54: 1850-1859
92. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet. 2008 ; 372: 1231-1239
93. Gotto AM, Moon JE. Recent clinical studies of the effects of lipid-modifying therapies. Am J Cardiol. 2012 ; 110: 15A - 26A
94. Lyons KS, McVeigh GE, Harbinson MT. Statins in heart failure-where do we stand?. Cardiovasc Drugs Ther. 2011 ; 25: 99-104
95. Tsouli SG, Liberopoulos EN, Goudevenos JA, et al. Should a statin be prescribed to every patient with heart failure?. Heart Fail Rev. 2008 ; 13: 211-225
96. Montecucco F, Mach F. Statins, ACE inhibitors and ARBs in cardiovascular disease. Best Pract Res Clin Endocrinol Metab. 2009 ; 23: 389-400
97. Ferrier KE, Muhlmann MH, Baguet JP, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol. 2002 ; 39: 1020-1025
98. Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999 ; 34: 1281-1286
99. Golomb BA, Dimsdale JE, White HL, et al. Reduction in blood pressure with statins: Results from the UCSD Statin Study, a randomized trial. Arch Intern Med. 2008 ; 168: 721-727
100. Ikeda T, Sakurai J, Nakayama D, et al. Pravastatin has an additional depressor effect in patients undergoing long-term treatment with antihypertensive drugs. Am J Hypertens. 2004 ; 17: 502-506
101. Kamberi LS, Bedri Bakalli A, Muhamet Budima N, et al. Pleiotropic and lipid-lowering effects of statins in hypertension. Mater Sociomed. 2012 ; 24: 84-86
102. Morgado M, Rolo S, Macedo AF, et al. Association of statin therapy with blood pressure control in hypertensive hypercholesterolemic outpatients in clinical practice. J Cardiovasc Dis Res. 2011 ; 2: 44-49
103. Seki S, Hashimoto K, Taniguchi I, et al. Effect of rosuvastatin on systemic blood pressure in patients with hypercholesterolemia. Exp Clin Cardiol. 2012 ; 17: 221-225
104. Borghi C, Prandin MG, Costa FV, et al. Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol. 2000 ; 35: 549-555
105. Mancia G, Parati G, Revera M, et al. Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: Evidence from PHYLLIS randomised double blind trial. Brit Med J. 2010 ; 340: c1197
106. Tonelli M, Sacks F, Pfeffer M, et al. Effect of pravastatin on blood pressure in people with cardiovascular disease. J Hum Hypertens. 2006 ; 20: 560-565
107. Owczarek J, Jasinska M, Drozdz J, et al. Concomitant administration of simvastatin with ivabradine in contrast to metoprolol intensifies slowing of heart rate in normo- and hypercholesterolemic rats. Arch Med Sci. 2012 ; 8: 549-554
108. Owczarek J, Jasinska M, Wejman I, et al. Effects of 4-week administration of simvastatin in different doses on heart rate and blood pressure after metoprolol injection in normocholesterolaemic and normotensive rats. Arch Med Sci. 2012 ; 8: 17-21
109. Strazzullo P, Kerry SM, Barbato A, et al. Do statins reduce blood pressure? A meta-analysis of randomized, controlled trials. Hypertension. 2007 ; 49: 792-798
110. Delbosc S, Cristol JP, Descomps B, et al. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension. 2002 ; 40: 142-147
111. Straznicky NE, Howes LG, Lam W, et al. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol. 1995 ; 75: 582-586
112. Tesfamariam B, Frohlich BH, Gregg RE. Differential effects of pravastatin, simvastatin, and atorvastatin on Ca2+ release and vascular reactivity. J Cardiovasc Pharmacol. 1999 ; 34: 95-101
113. Sim JS, Dick JB, Struthers AD. Statin therapy increases vascular sensitivity to angiotensin II in hypercholesterolaemic patients. J Renin Angiotensin Aldosterone Syst. 2004 ; 5: 109-113
114. Ufnal M, Drapala A, Sikora M, et al. Oral simvastatin reduces the hypertensive response to air-jet stress. Clin Exp Pharmacol Physiol. 2012 ; 39: 350-356
115. Ufnal M, Sikora M, Zera T, et al. Simvastatin reduces pressor response to centrally administered angiotensin II. Am J Hypertens. 2010 ; 23: 956-959
116. Gao L, Wang W, Li YL, et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: Roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation. 2005 ; 112: 1763-1770
117. Mateos L, Ismail MA, Gil-Bea FJ, et al. Upregulation of brain renin angiotensin system by 27-hydroxycholesterol in Alzheimer's disease. J Alzheimers Dis. 2011 ; 24: 669-679
118. Kalayci R, Kaya M, Uzun H, et al. Influence of hypercholesterolemia and hypertension on the integrity of the blood-brain barrier in rats. Int J Neurosci. 2009 ; 119: 1881-1904
119. Ledingham JM, Laverty R. Effect of simvastatin given alone and in combination with valsartan or enalapril on blood pressure and the structure of mesenteric resistance arteries and the basilar artery in the genetically hypertensive rat model. Clin Exp Pharmacol Physiol. 2005 ; 32: 76-85
120. Koh KK, Son JW, Ahn JY, et al. Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension. 2004 ; 44: 180-185
121. Bayorh MA, Ganafa AA, Eatman D, et al. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. Am J Hypertens. 2005 ; 18: 1496-1502
122. Duprez DA. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: A clinical review. J Hypertens. 2006 ; 24: 983-991
123. Dzau VJ. Theodore Cooper lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension. 2001 ; 37: 1047-1052
124. Corsini A, Arnaboldi L, Raiteri M, et al. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228)on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol Res. 1996 ; 33: 55-61
125. Laufs U, Marra D, Node K, et al. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999 ; 274: 21926-21931
126. Ruperez M, Rodrigues-Diez R, Blanco-Colio LM, et al. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: Role of RhoA/ROCK and MAPK pathways. Hypertension. 2007 ; 50: 377-383
127. Ichiki T, Takeda K, Tokunou T, et al. Downregulation of angiotensin II type 1 receptor by hydrophobic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001 ; 21: 1896-1901
128. Nickenig G, Baumer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation. 1999 ; 100: 2131-2134
129. Zimmerman MC, Lazartigues E, Lang JA, et al. Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res. 2002 ; 91: 1038-1045
130. Sugimoto K, Fujimura A. Different effects of simvastatin and pravastatin on adrenal sensitivity to angiotensin II. Br J Clin Pharmacol. 2003 ; 56: 696-697
131. Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: Involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol. 2001 ; 59: 646-654
132. Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res. 2002 ; 51: 58-62
133. Zelvyte I, Dominaitiene R, Crisby M, et al. Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res. 2002 ; 45: 147-154
134. Takeda K, Ichiki T, Tokunou T, et al. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation. 2000 ; 102: 1834-1839
135. Daugherty A, Rateri DL, Lu H, et al. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation. 2004 ; 110: 3849-3857
136. Nickenig G, Jung O, Strehlow K, et al. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol. 1997 ; 272: H2701 - H2707
137. Nickenig G, Sachinidis A, Michaelsen F, et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation. 1997 ; 95: 473-478
138. Nickenig G. Should angiotensin II receptor blockers and statins be combined?. Circulation. 2004 ; 110: 1013-1020
139. Warnholtz A, Nickenig G, Schulz E, et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: Evidence for involvement of the renin-angiotensin system. Circulation. 1999 ; 99: 2027-2033
140. Castejon AM, Zollner E, Tristano A, et al. Upregulation of angiotensin II-AT1 receptors during statin withdrawal in vascular smooth muscle cells. J Cardiovasc Pharmacol. 2007 ; 50: 708-711
141. Hattangady NG, Olala LO, Bollag WB, et al. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol. 2012 ; 350: 151-162
142. Ide H, Fujiya S, Aanuma Y, et al. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones. Clin Ther. 1990 ; 12: 410-420
143. Paulsen L, Holm C, Bech JN, et al. Effects of statins on renal sodium and water handling: Acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans. Nephrol Dial Transplant. 2008 ; 23: 1556-1561
144. Frishman WH, Horn J. Statin-drug interactions: Not a class effect. Cardiol Rev. 2008 ; 16: 205-212
145. Bolego C, Baetta R, Bellosta S, et al. Safety considerations for statins. Curr Opin Lipidol. 2002 ; 13: 637-644
146. Huddy K, Dhesi P, Thompson PD. Do the frequencies of adverse events increase, decrease, or stay the same with long-term use of statins?. Curr Atheroscler Rep. 2013 ; 15: 301-309